Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Leukemia 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Gastrointestinal Stromal Tumors 13Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid 6Brain Neoplasms 6Prostatic Neoplasms 5Philadelphia Chromosome 5Blast Crisis 5Sarcoma 4Recurrence 4Glioblastoma 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Ovarian Neoplasms 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Stomach Neoplasms 2Polycythemia Vera 2Neurofibromatoses 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Meningioma 2

Interventions

fludarabine phosphate 43Whole-Body Irradiation 36Mycophenolic Acid 36Peripheral Blood Stem Cell Transplantation 31Cyclophosphamide 31Tacrolimus 28Busulfan 22Antilymphocyte Serum 21Cyclosporine 19fludarabine 17ruxolitinib 16Melphalan 16Methotrexate 15Cytarabine 12thymoglobulin 9Sirolimus 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Filgrastim 8Cyclosporins 8Radiotherapy 7Cord Blood Stem Cell Transplantation 7Rituximab 6Alemtuzumab 6merphos 5Stem Cell Transplantation 5Flow Cytometry 5Azacitidine 5sargramostim 4ponatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Myeloproliferative Disorders × Imatinib Mesylate × Clear all
NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00245128 2012-01-13

Imatinib Mesylate in Treating Patients With Myelofibrosis

OHSU Knight Cancer Institute

Phase 2 Terminated
10 enrolled 6 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡